Please provide your email address to receive an email when new articles are posted on . In a randomized double blind, placebo-controlled trial with older men assigned either AndroGel 1% (transdermal ...

In the authors’ opinion and clinical experience, daily gel application can be disruptive to a patient’s routine. In theory, a higher concentration product should be more convenient because of lower ...

CHICAGO --Testosterone treatment did not improve older men’s memory or mental function in the latest results from landmark government research that challenges the anti-aging claims of popular ...

Upsher-Smith Laboratories announced it has received final approval from the FDA for its New Drug Application (NDA) for Vogelxo (testosterone) gel for topical use. Vogelxo is a Schedule CIII androgen ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am an 84-year-old male. I recently switched from ...

Endo Pharmaceuticals Receives FDA Approval for FORTESTA(TM) (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone FORTESTA Gel is the first approved testosterone ...

Testosterone cream is a needle-free testosterone therapy that can effectively raise hormone levels. Benefits include improved reproductive function, mood, and energy, but it also carries the same ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. BPAX reports a New Drug Application (NDA) has been accepted for filing by the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...